Kinzalkomb (Hydrochlorothiazide, Telmisartan)

Telmisartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urine output. Together they lower vascular resistance and plasma volume, producing a synergistic blood‑pressure‑lowering effect.

The specific dose of Kinzalkomb is determined by the prescribing clinician based on the patient’s blood‑pressure level, renal function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Kinzalkomb is classified as Pregnancy Category D, indicating evidence of risk to the fetus, and it is generally contraindicated during pregnancy. Caution is also advised while breastfeeding, and the prescriber should evaluate the risk‑benefit ratio before use.

To request Kinzalkomb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kinzalkomb combines an angiotensin II receptor blocker with a thiazide diuretic, offering a single‑pill solution that can simplify therapy compared with taking two separate agents. This combination often provides greater blood‑pressure reduction than either component alone, while maintaining a safety profile comparable to other combination products.

Kinzalkomb should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Kinzalkomb is taken orally as a whole tablet, usually once daily. It may be taken with or without food, but patients should swallow the tablet with a full glass of water and avoid crushing or chewing it.

Serious adverse events include severe dehydration, hyperkalemia, acute renal impairment, and angioedema or other severe allergic reactions. Patients should seek immediate medical attention if they experience symptoms such as rapid weight loss, swelling of the face or throat, severe weakness, or marked changes in urine output.

Kinzalkomb is contraindicated in patients with known hypersensitivity to either component, in pregnant women, and in individuals with severe renal impairment or uncontrolled hyperkalemia. Caution is also advised for patients with a history of angioedema related to ACE inhibitors or ARBs.